Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology

The Search for Answers: Diagnostic Testing and Evaluation

At a Glance

Diagnosing IPAN or pure autonomic failure requires autonomic reflex testing plus a careful search for treatable look-alikes such as diabetes, vitamin B12 deficiency, autoimmune disease, cancer-related syndromes, and amyloidosis. Skin biopsy can support the evaluation but cannot prove the diagnosis.

Diagnosing Idiopathic Peripheral Autonomic Neuropathy (IPAN) or Pure Autonomic Failure (PAF) is a process that involves a systematic evaluation [1]. Because these are rare conditions, your doctors must perform a rigorous investigation to ensure your symptoms aren’t caused by a different, potentially treatable disease [2][3].

This journey typically involves two main parts: an advanced battery of tests to measure your autonomic function, and a targeted evaluation to evaluate for look-alike conditions [4][1].

Part 1: The Autonomic Reflex Screen (ARS)

The ARS is a standardized assessment used to document exactly how your autonomic nervous system is malfunctioning. It isn’t just one test, but a suite of four assessments performed in a specialized laboratory [4]:

  1. QSART (Sudomotor Test): Small capsules are placed on your skin to measure how your sweat glands respond to a chemical stimulus. This checks your postganglionic nerves—the nerve fibers that connect directly to target organs like sweat glands, furthest from your spine [1][5].
  2. Cardiovagal Testing (Deep Breathing): You will be asked to breathe deeply and slowly while your heart rate is monitored. A healthy nervous system changes your heart rate significantly as you breathe; a “flat” response suggests autonomic damage [5][6].
  3. Valsalva Maneuver: You will blow into a tube against resistance. This measures how your blood pressure and heart rate recover from a brief moment of strain [7].
  4. Tilt-Table Test: You lie on a table that is tilted upright. This documents orthostatic blood pressure behavior. When a sustained fall in blood pressure is accompanied by an inappropriately small heart-rate increase, it supports a diagnosis of neurogenic orthostatic hypotension (nOH) (distinguishing it from non-neurogenic causes like simple dehydration) [8][7].

What to Expect at Autonomic Testing: You may be asked to hold certain medications prior to the test—this must be directed by the testing center and never done independently. You may also receive specific instructions regarding fasting, caffeine, and nicotine. Because the tests deliberately provoke blood pressure changes, you may experience dizziness, and you should arrange for safe transportation home.

The CASS Score

Your results are combined into a Composite Autonomic Severity Score (CASS) [4]. This score, usually ranging from 0 to 10, grades your impairment in three areas: sudomotor (sweating), cardiovagal (heart rate), and adrenergic (blood pressure) [9]. A higher CASS score indicates more widespread autonomic failure [10], but does not establish etiology or predict your future by itself.

Part 2: Evaluating the “Look-Alikes”

To reach an “idiopathic” diagnosis, your care team must evaluate for several specific conditions that can mimic PAF or IPAN.

Examples to Discuss

Not every patient needs every test, but ensure your doctor has evaluated for these common and rare causes:

  • [ ] Diabetes: Evaluated via HbA1c or an oral glucose tolerance test [11].
  • [ ] Vitamin B12 Deficiency: Can cause nerve damage that mimics autonomic failure [12].
  • [ ] Autoimmune Autonomic Ganglionopathy (AAG): This is evaluated with a blood test for anti-gAChR antibodies. If these are present, your body is attacking its own autonomic “junctions.” However, a negative test does not exclude seronegative autoimmune disease [12][9].
  • [ ] Sjögren’s Syndrome: Often missed, this requires checking for specific antibodies (anti-Ro/SSA) or even a minor salivary gland biopsy if you have dry eyes or mouth [13][14].
  • [ ] Paraneoplastic Syndromes: In some cases, autonomic failure can be an early sign of an undiagnosed cancer. Doctors may screen for specific “neuronal antibodies” or order imaging depending on your individual risk factors [12][15].

Amyloidosis: A Crucial Evaluation

Amyloidosis is a condition where “misfolded” proteins build up in your organs and nerves [16]. It is vital to evaluate for this because its treatments are very different from those for PAF.

  • AL Amyloidosis: Evaluated using serum free light chain testing and immunofixation (blood and urine) to look for abnormal proteins [17][18].
  • ATTR Amyloidosis: TTR genetic sequencing can identify inherited variants. However, a negative genetic test does not exclude non-hereditary “wild-type” ATTR amyloidosis [19].
  • Biopsy: If amyloidosis is suspected, a doctor may perform a “fat pad aspirate” or skin biopsy and stain it with Congo red dye to look for a specific “apple-green” glow under a microscope. Because test sensitivity varies, a negative surrogate biopsy does not reliably exclude amyloidosis [16][20].

The Role of Skin Biopsy in PAF

A skin biopsy can be a supportive adjunct tool, though it is not a standalone definitive proof of PAF [3]. Pathologists look for two things:

  1. Small Fiber Density (IENFD): They count the microscopic nerve fibers in your skin. A low count (denervation) supports small-fiber loss but does not prove its cause [21][22].
  2. Phosphorylated Alpha-Synuclein: This is a specific “signature” protein found in the nerves of people with PAF [3][22]. Finding this protein in your skin nerves can provide supportive evidence of a “synucleinopathy” [23][24]. However, testing is specialized, not universally standardized, positive deposits can occur across other synucleinopathies (like Parkinson’s or MSA), and a negative result does not exclude PAF.

Common questions in this guide

What tests are used to evaluate IPAN or pure autonomic failure?
Doctors commonly start with an autonomic reflex screen, a group of tests that includes a sweat test called QSART, deep breathing, the Valsalva maneuver, and a tilt-table test. Together, these assess sweating, heart-rate, and blood-pressure control. The team also looks for other conditions that can cause similar symptoms before labeling the problem idiopathic.
What does the CASS score tell me?
The Composite Autonomic Severity Score, or CASS, combines results for sweating, heart-rate control, and blood-pressure control. It usually ranges from 0 to 10, and a higher score indicates more widespread autonomic impairment. The score does not identify the cause of the problem or predict how the condition will progress.
Why do I need testing for other diseases before an IPAN diagnosis?
Diabetes, vitamin B12 deficiency, autoimmune autonomic ganglionopathy, Sjögren’s syndrome, paraneoplastic syndromes, and amyloidosis can produce similar autonomic problems. These conditions may need different treatments, so identifying them is important. The exact tests depend on your symptoms, examination, and individual risk factors.
Can normal tests rule out amyloidosis?
Normal blood and urine studies make AL amyloidosis less likely, but they do not answer every amyloidosis question. A negative TTR genetic test does not rule out wild-type ATTR amyloidosis, and a negative fat-pad or skin biopsy may not fully exclude amyloidosis because test sensitivity varies. Your doctor may recommend additional evaluation based on your symptoms and results.
What if my ganglionic antibody test is negative?
A negative anti-gAChR antibody test makes autoimmune autonomic ganglionopathy less likely, but it does not exclude an autoimmune cause. Some people have antibody-negative, or seronegative, autoimmune disease. Your neurologist interprets the result alongside the onset of symptoms, examination, and other tests.
How can a skin biopsy help with a PAF evaluation?
A skin biopsy may measure small-fiber density and look for phosphorylated alpha-synuclein in skin nerves. Reduced small-fiber density supports nerve-fiber loss, while alpha-synuclein deposits may support a synuclein-related disorder such as PAF. The biopsy is supportive rather than definitive: a positive result is not unique to PAF, and a negative result does not rule it out.
How should I prepare for autonomic testing?
Follow the testing center’s instructions about medicines, fasting, caffeine, and nicotine, and do not stop a medicine on your own. The tests can temporarily cause dizziness because they deliberately challenge blood-pressure control. Arrange safe transportation home if the center recommends it or if you may feel unwell afterward.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my autonomic reflex screen use age- and sex-adjusted normative values to calculate my CASS score?
  2. 2.What specifically does my 'adrenergic' score tell us about how my nerves control my blood pressure?
  3. 3.Were my serum free light chain levels and immunofixation tests normal, and does that fully rule out AL amyloidosis?
  4. 4.Do you recommend TTR genetic testing to check for hereditary amyloidosis, even if I don't have a family history?
  5. 5.If my ganglionic antibody (AAG) test was negative, is there still a possibility of a 'seronegative' autoimmune cause?
  6. 6.Does my skin biopsy show the specific phosphorylated alpha-synuclein pattern typical of PAF, and how does this help rule out other conditions like MSA?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Updates on the Diagnosis and Treatment of Peripheral Autonomic Neuropathies.

    Lamotte G, Sandroni P

    Current neurology and neuroscience reports 2022; (22(12)):823-837 doi:10.1007/s11910-022-01240-4.

    PMID: 36376534
  2. 2

    Autonomic Peripheral Neuropathy.

    Freeman R

    Continuum (Minneapolis, Minn.) 2020; (26(1)):58-71 doi:10.1212/CON.0000000000000825.

    PMID: 31996622
  3. 3

    Pure autonomic failure and the differential diagnosis of autonomic peripheral neuropathies.

    González-Duarte A, Varma-Doyle A, Freeman R

    Current opinion in neurology 2021; (34(5)):675-682 doi:10.1097/WCO.0000000000000985.

    PMID: 34392300
  4. 4

    Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology.

    Cheshire WP, Freeman R, Gibbons CH, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2021; (132(2)):666-682 doi:10.1016/j.clinph.2020.11.024.

    PMID: 33419664
  5. 5

    An updated normative data set from the autonomic reflex screen representative of Southwestern Ontario.

    Baker J, Kimpinski K

    Canadian journal of physiology and pharmacology 2019; (97(2)):107-111 doi:10.1139/cjpp-2018-0611.

    PMID: 30517028
  6. 6

    Establishment of Normative Data for Autonomic Function Tests in Indian Population.

    Singh S, Jaison V, Khatter H, et al.

    Annals of Indian Academy of Neurology 2022; (25(3)):457-463 doi:10.4103/aian.aian_579_21.

    PMID: 35936597
  7. 7

    Standardized Autonomic Testing in Patients With Probable Radiation-Induced Afferent Baroreflex Failure.

    Lamotte G, Coon EA, Suarez MD, et al.

    Hypertension (Dallas, Tex. : 1979) 2022; (79(1)):50-56 doi:10.1161/HYPERTENSIONAHA.121.17805.

    PMID: 34739766
  8. 8

    Autonomic uprising: the tilt table test in autonomic medicine.

    Cheshire WP, Goldstein DS

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(2)):215-230 doi:10.1007/s10286-019-00598-9.

    PMID: 30838497
  9. 9

    Ganglionic Antibody Level as a Predictor of Severity of Autonomic Failure.

    Cutsforth-Gregory JK, McKeon A, Coon EA, et al.

    Mayo Clinic proceedings 2018; (93(10)):1440-1447 doi:10.1016/j.mayocp.2018.05.033.

    PMID: 30170741
  10. 10

    The phenotype of "pure" autonomic failure.

    Coon EA, Badihian N, McCarter SJ, et al.

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2025; (35(3)):477-485 doi:10.1007/s10286-025-01121-z.

    PMID: 40053259
  11. 11

    Autonomic Dysfunction from Diagnosis to Treatment.

    Peltier AC

    Primary care 2024; (51(2)):359-373 doi:10.1016/j.pop.2024.02.006.

    PMID: 38692780
  12. 12

    Autoimmune autonomic disorders.

    Mckeon A, Benarroch EE

    Handbook of clinical neurology 2016; (133()):405-16.

    PMID: 27112689
  13. 13

    Spectrum of Autonomic Nervous System Impairment in Sjögren Syndrome.

    Goodman BP, Crepeau A, Dhawan PS, et al.

    The neurologist 2017; (22(4)):127-130 doi:10.1097/NRL.0000000000000134.

    PMID: 28644253
  14. 14

    Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances.

    Golden EP, Vernino S

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(3)):277-288 doi:10.1007/s10286-019-00611-1.

    PMID: 31093868
  15. 15

    Paraneoplastic autoimmune autonomic ganglionopathy as the first symptom of bladder cancer: a case report and review of literature.

    de Rojas Leal C, Lage-Sánchez JM, Pinel-Ríos J, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(8)):4841-4845 doi:10.1007/s10072-022-06075-y.

    PMID: 35482157
  16. 16

    Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.

    Gertz MA

    American journal of hematology 2024; (99(2)):309-324 doi:10.1002/ajh.27177.

    PMID: 38095141
  17. 17

    A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

    Muchtar E, Gertz MA, Kyle RA, et al.

    Mayo Clinic proceedings 2019; (94(3)):472-483 doi:10.1016/j.mayocp.2018.08.006.

    PMID: 30770096
  18. 18

    Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

    Phull P, Sanchorawala V, Connors LH, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2018; (25(1)):62-67 doi:10.1080/13506129.2018.1436048.

    PMID: 29424556
  19. 19

    [Cardiac amyloidosis: State of art in 2022].

    Oghina S, Delbarre MA, Poullot E, et al.

    La Revue de medecine interne 2022; (43(9)):537-544 doi:10.1016/j.revmed.2022.04.036.

    PMID: 35870985
  20. 20

    Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.

    Zanwar S, Gertz MA, Muchtar E

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(1)):83-90 doi:10.6004/jnccn.2022.7077.

    PMID: 36630897
  21. 21

    Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease.

    Donadio V, Incensi A, Piccinini C, et al.

    Annals of neurology 2016; (79(2)):306-16 doi:10.1002/ana.24567.

    PMID: 26606657
  22. 22

    Cutaneous phosphorylated-synuclein: an early diagnostic biomarker for pure autonomic failure.

    Koay S, Provitera V, Caporaso G, et al.

    Journal of neurology, neurosurgery, and psychiatry 2025; (96(5)):500-507 doi:10.1136/jnnp-2024-334615.

    PMID: 39608812
  23. 23

    Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies.

    Gibbons CH, Levine T, Adler C, et al.

    JAMA 2024; (331(15)):1298-1306 doi:10.1001/jama.2024.0792.

    PMID: 38506839
  24. 24

    Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.

    Donadio V, Incensi A, El-Agnaf O, et al.

    Scientific reports 2018; (8(1)):14246 doi:10.1038/s41598-018-32588-8.

    PMID: 30250046

This page explains IPAN and PAF diagnostic testing for informational purposes only and does not constitute medical advice. A neurologist and the autonomic testing team should interpret your results and decide which additional evaluations are appropriate.

Get notified when new evidence is published on idiopathic peripheral autonomic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.